PE20151432A1 - Formulaciones de lorazepam de liberacion sostenida - Google Patents

Formulaciones de lorazepam de liberacion sostenida

Info

Publication number
PE20151432A1
PE20151432A1 PE2015001248A PE2015001248A PE20151432A1 PE 20151432 A1 PE20151432 A1 PE 20151432A1 PE 2015001248 A PE2015001248 A PE 2015001248A PE 2015001248 A PE2015001248 A PE 2015001248A PE 20151432 A1 PE20151432 A1 PE 20151432A1
Authority
PE
Peru
Prior art keywords
sustained release
release lorazepam
formulations
lorazepam formulations
lorazepam
Prior art date
Application number
PE2015001248A
Other languages
English (en)
Inventor
Douglas A Saltel
Michael Vachon
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50064764&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151432(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of PE20151432A1 publication Critical patent/PE20151432A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referida a una composicion farmaceutica caracterizada porque comprende: (i) perlas de liberacion sostenida de lorazepam, (ii) perlas de liberacion sostenida retardada de lorazepam. La cantidad total de lorazepam contenido en la composicion es de 0.5 a 10 mg
PE2015001248A 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion sostenida PE20151432A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750797P 2013-01-09 2013-01-09
US201361762833P 2013-02-08 2013-02-08

Publications (1)

Publication Number Publication Date
PE20151432A1 true PE20151432A1 (es) 2015-09-23

Family

ID=50064764

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001248A PE20151432A1 (es) 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberacion sostenida

Country Status (30)

Country Link
US (3) US8999393B1 (es)
EP (1) EP2943185B1 (es)
JP (2) JP6039823B2 (es)
KR (1) KR102318274B1 (es)
CN (1) CN105209018B (es)
AU (1) AU2014205440B2 (es)
BR (1) BR112015016304A8 (es)
CA (1) CA2897302C (es)
CL (1) CL2015001920A1 (es)
CY (1) CY1123933T1 (es)
DK (1) DK2943185T3 (es)
ES (1) ES2856181T3 (es)
HK (1) HK1213770A1 (es)
HR (1) HRP20210236T1 (es)
HU (1) HUE054005T2 (es)
IL (1) IL239777B (es)
LT (1) LT2943185T (es)
MX (1) MX367364B (es)
NZ (1) NZ710860A (es)
PE (1) PE20151432A1 (es)
PH (1) PH12015501534B1 (es)
PL (1) PL2943185T3 (es)
PT (1) PT2943185T (es)
RS (1) RS61857B1 (es)
RU (1) RU2678324C2 (es)
SG (1) SG11201505349RA (es)
SI (1) SI2943185T1 (es)
UA (1) UA117233C2 (es)
WO (1) WO2014110245A1 (es)
ZA (1) ZA201505082B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
JP7110366B2 (ja) * 2017-11-01 2022-08-01 エッジモント・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー・トラスト ロラゼパムのアルコール耐性経口用医薬組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (es) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
AU552261B2 (en) * 1980-01-21 1986-05-29 Wellcome Foundation Limited, The Use of propiophenone derivatives as adjuncts to benzo- diazepine tranquillisers
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
AU747549B2 (en) * 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
JP2002541092A (ja) * 1999-04-06 2002-12-03 ファーマクエスト・リミテッド メチルフェニデートのパルス性送達のための薬学的投薬形態
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
EP1250937B1 (en) 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
KR100892333B1 (ko) 2001-07-10 2009-04-08 테바 파마슈티컬 인더스트리즈 리미티드 0차, 0차-2상, 증가적 또는 감소적 약물 전달을 위한 약물전달 시스템
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
ATE425744T1 (de) 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
AU2006214443C1 (en) * 2005-02-15 2011-11-24 Alkermes Pharma Ireland Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
US8277840B2 (en) 2005-07-22 2012-10-02 Emcure Pharmaceuticals Limited Sustained release formulation of alprazolam
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009522272A (ja) * 2005-12-30 2009-06-11 ミドルブルック ファーマスーティカルス，インコーポレイテッド 薬剤送達のための胃内放出パルスシステム
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
BRPI0716196A2 (pt) * 2006-08-31 2013-11-12 Eurand Inc Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008068584A2 (en) 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
WO2009137067A1 (en) * 2008-05-08 2009-11-12 Supernus Pharmaceuticals Inc. Controlled release formulations of alprazolam
CN102245171A (zh) 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
WO2014110245A1 (en) 2014-07-17
DK2943185T3 (da) 2021-02-15
RU2015128915A (ru) 2017-02-10
CN105209018B (zh) 2019-06-25
IL239777B (en) 2019-03-31
LT2943185T (lt) 2021-03-10
CY1123933T1 (el) 2022-05-27
US20150174078A1 (en) 2015-06-25
EP2943185A1 (en) 2015-11-18
SI2943185T1 (sl) 2021-04-30
KR20150118119A (ko) 2015-10-21
US20160228378A1 (en) 2016-08-11
US20150110874A1 (en) 2015-04-23
CA2897302C (en) 2022-05-31
MX367364B (es) 2019-08-16
BR112015016304A8 (pt) 2018-01-23
CN105209018A (zh) 2015-12-30
PL2943185T3 (pl) 2022-01-17
IL239777A0 (en) 2015-08-31
RS61857B1 (sr) 2021-06-30
SG11201505349RA (en) 2015-08-28
AU2014205440B2 (en) 2018-07-05
US8999393B1 (en) 2015-04-07
EP2943185B1 (en) 2020-11-18
JP2017019880A (ja) 2017-01-26
NZ710860A (en) 2020-05-29
BR112015016304A2 (pt) 2017-07-11
RU2678324C2 (ru) 2019-01-28
HK1213770A1 (zh) 2016-07-15
ZA201505082B (en) 2021-04-28
PT2943185T (pt) 2021-02-18
HRP20210236T1 (hr) 2021-03-19
PH12015501534A1 (en) 2015-10-05
ES2856181T3 (es) 2021-09-27
KR102318274B1 (ko) 2021-10-26
UA117233C2 (uk) 2018-07-10
MX2015008756A (es) 2016-03-31
JP2016504390A (ja) 2016-02-12
CL2015001920A1 (es) 2016-01-29
CA2897302A1 (en) 2014-07-17
AU2014205440A1 (en) 2015-08-27
PH12015501534B1 (en) 2015-10-05
HUE054005T2 (hu) 2021-08-30
JP6039823B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001547A1 (es) Composiciones para el cuidado oral
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
GT201400111A (es) Triazolopiridinas sustituidas
PE20151778A1 (es) Formulacion combinada de dos compuestos antivirales
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
AR082215A1 (es) Composicion farmaceutica agradable al paladar
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
CR20150275A (es) Composición de difenidol de liberación prolongada
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
AR098614A1 (es) Compuesto para el tratamiento de hipoglicemia severa
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
EA201492280A1 (ru) Стабильный состав пексиганана
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.

Legal Events

Date Code Title Description
FG Grant, registration